Live Breaking News & Updates on European Renal Association Congress

Stay updated with breaking news from European renal association congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year ....

David-soergel , David-kavanagh , Newcastle-university , European-medicines-agency , Novartis , European-renal-association-congress , Drug-administration ,

Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress

Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress 28 May 2024, Glasgow, Scotland – Mironid… ....

Sweden , United-kingdom , Glasgow , Glasgow-city , Stockholm , Scotland , Sukaina-virji-lindsey-neville , Adele-rowley , European-renal-association-congress , European-renal-association , Mironid-presents-translational-data , Oral-presentation

Novartis rides IgAN trioka to 2 trial wins in rare kidney diseases

Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles. ....

Switzerland , Swiss , Shreeram-aradhye , Travere-filspari , Willima-blair , William-blair , European-renal-association-congress , Novartis , European-renal-association , Travere-therapeutic , Leerink-partners ,

Monoclonal Antibody May Benefit Patients With Kidney Transplant Rejection

But results were not fully durable after treatment cessation ....

Vienna , Wien , Austria , Stockholm , Sweden , New-york , United-states , Katharina-mayer , European-renal-association-congress , University-of-vienna , Medical-university , New-england-journal

Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk

Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.“These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” Vlado Perkovic, MB, PS, PhD, ....

Sydney , New-south-wales , Australia , Stockholm , Sweden , Vlado-perkovic , Bymarke-neumann , Gina-brockenbrough , European-renal-association-congress , University-of-new-south-wales , Novo-nordisk , Evaluate-renal-function